KRISTINA BRAATEN: Open Payments
NPI 1699420026 · SEATTLE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$802 in 11 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $113 · 2025 $802
Food & beverage: $802
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 2 | $254 |
| Daiichi Sankyo Inc. | 2 | $143 |
| E.R. Squibb & Sons, L.L.C. | 1 | $110 |
| Janssen Scientific Affairs, LLC | 1 | $105 |
| Sandoz Inc. | 1 | $80 |
| Amgen Inc. | 1 | $48 |
| ABBVIE INC. | 2 | $32 |
| Novartis Pharmaceuticals Corporation | 1 | $30 |
Products named: RYBREVANT, DATROWAY, REBLOZYL, DARZALEX, IMDELLTRA (AMG757), VENCLEXTA, KISQALI, Enhertu.
Industry payments across WA — which companies pay providers there.
